ICOPMAP SPECIAL EDITION Literature review: A comparison of the efficacy of artemether-lumefantrine (AL) versus dihydroartemisinin-piperaquine (DHP) for the treatment of uncomplicated malaria in patients
DOI:
https://doi.org/10.46542/pe.2025.252.8994Keywords:
Artemether-lumefantrine, Dihydroartemisinin-piperaquine, Mosquito-borne disease, Multidrug-resistant, Uncomplicated malariaAbstract
Background: Malaria, a life-threatening disease caused by Plasmodium parasites, poses a persistent global health challenge exacerbated by rising multidrug resistance (MDR). While artemisinin-based combination therapies (ACTs) have significantly reduced malaria mortality, the threat of resistance highlights the need for optimised treatment strategies.
Objective: This literature review compares the therapeutic efficacy of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DHP) in the treatment of uncomplicated malaria to inform treatment optimisation.
Method: A review of literature published between 2019 and 2024 was undertaken, encompassing 13 peer-reviewed studies from PubMed, ScienceDirect, and Google Scholar. The findings were synthesised narratively.
Result: Analysis reveals robust efficacy for both AL (96–98.6%) and DHP (98.8–100%), surpassing the World Health Organisation’s 95% efficacy benchmark. Notably, DHP demonstrated superior results in most studies.
Conclusion: The study highlights the consistent efficacy of AL and DHP, with DHP showing a slight advantage. These insights underscore the importance of maintaining sustained surveillance of antimalarial resistance and adhering to best practices in endemic regions.
References
Abamecha, A., Yilma, D., Addisu, W., El-Abid, H., Ibenthal, A., Noedl, H., Yewhalaw, D., Moumni, M., & Abdissa, A. (2020). Therapeutic efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Chewaka District, Ethiopia. Malaria Journal, 19(1), 240. https://doi.org/10.1186/s12936-020-03307-4
Asih, P. B. S., Rozi, I. E., Dewayanti, F. K., Wangsamuda, S., Zulfah, S., Robaha, M., Hutahaean, J., Anggraeni, N. D., Kusumaningsih, M., Mulyani, P. S., Sariwati, E., Basri, H. H., Bustos, M. D. G., & Syafruddin, D. (2022). Efficacy and safety of dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Papua and Sumatra, Indonesia. Malaria journal, 21(1), 95. https://doi.org/10.1186/s12936-022-04101-0
Bate, R., Tren, R., Hess, K., & Attaran, A. (2009). Physical and chemical stability of expired fixed dose combination artemether-lumefantrine in uncontrolled tropical conditions. Malaria Journal, 8(1). https://doi.org/10.1186/1475-2875-8-33
Byakika-Kibwika, P., Lamorde, M., Mayanja-Kizza, H., Merry, C., Colebunders, B., & van Geertruyden, J. P. (2010). Update on the efficacy, effectiveness and safety of artemether- lumefantrine combination therapy for treatment of uncomplicated malaria. Therapeutics and Clinical Risk Management, 6, 11–20. https://doi.org/10.2147/tcrm.s4483
Diarra, Y., Koné, O., Sangaré, L., Doumbia, L., Haidara, D. B. Ben, Diallo, M., Maiga, A., Sango, H. A., Sidibé, H., Mihigo, J., Nace, D., Ljolje, D., Talundzic, E., Udhayakumar, V., Eckert, E., Woodfill, C. J., Moriarty, L. F., Lim, P., Krogstad, D. J., … Koita, O. A. (2021). Therapeutic efficacy of artemether–lumefantrine and artesunate–amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Mali, 2015–2016. Malaria Journal, 20(1). https://doi.org/10.1186/s12936-021-03760-9
Duru, V., Witkowski, B., & Ménard, D. (2016). Plasmodium falciparum resistance to artemisinin derivatives and piperaquine: A major challenge for malaria Elimination in Cambodia. The American journal of tropical medicine and hygiene, 95(6), 1228–1238. https://doi.org/10.4269/ajtmh.16-0234
Gansané, A., Moriarty, L. F., Ménard, D., Yerbanga, I., Ouedraogo, E., Sondo, P., Kinda, R., Tarama, C., Soulama, E., Tapsoba, M., Kangoye, D., Compaore, C. S., Badolo, O., Dao, B., Tchwenko, S., Tinto, H., & Valea, I. (2021). Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018. Malaria Journal, 20(1). https://doi.org/10.1186/s12936-021-03585-6
Hamaluba, M., van der Pluijm, R. W., Weya, J., Njuguna, P., Ngama, M., Kalume, P., Mwambingu, G., Ngetsa, C., Wambua, J., Boga, M., Mturi, N., Lal, A. A., Khuroo, A., Taylor, W. R.J., Gonçalves, S., Miotto, O., Dhorda, M., Mutinda, B., Mukaka, M., … Dondorp, A. M. (2021). Arterolane–piperaquine–mefloquine versus arterolane–piperaquine and artemether– lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a single-centre, open-label, randomised, non-inferiority trial. The Lancet Infectious Diseases, 21(10), 1395–1406. https://doi.org/10.1016/S1473-3099(20)30929-4
Keighley, C., Cooley, L., Morris, A. J., Ritchie, D., Clark, J. E., Boan, P., & Worth, L. J. (2021). Consensus guidelines for the diagnosis and management of invasive candidiasis in haematology, oncology and intensive care settings, 2021. Internal Medicine Journal, 51(S7), 89–117. https://doi.org/10.1111/imj.15589
Kpemasse, A., Dagnon, F., Saliou, R., Yarou Maye, A. S., Affoukou, C. D., Zoulkaneri, A., Guézo-Mévo, B., Moriarty, L. F., Ndiaye, Y. D., Garba, M. N., Deme, A. B., Ndiaye, D., & Hounto, A. O. (2021). Efficacy of artemether-lumefantrine for the treatment of Plasmodium falciparum malaria in Bohicon and Kandi, Republic of Benin, 2018-2019. The American journal of tropical medicine and hygiene, 105(3), 670–676. https://doi.org/10.4269/ajtmh.21-0086
Leong, F. J., Jain, J. P., Feng, Y., Goswami, B., & Stein, D. S. (2018). A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine. Malaria journal, 17(1), 7. https://doi.org/10.1186/s12936-017-2162-8
Lohy Das, J., Rulisa, S., de Vries, P. J., Mens, P. F., Kaligirwa, N., Agaba, S., Tarning, J., Karlsson, M. O., & Dorlo, T. P. C. (2018). Population pharmacokinetics of artemether, dihydroartemisinin, and lumefantrine in Rwandese pregnant women treated for uncomplicated Plasmodium falciparum malaria. Antimicrobial agents and chemotherapy, 62(10), e00518-18. https://doi.org/10.1128/AAC.00518-18
Malmberg, Maja (2012). The role of molecular markers in emerging artemether-lumefantrine resistant Plasmodium falciparum. [Thesis, Karolinska Institutet]. https://hdl.handle.net/10616/41337
Marwa, K. J., Konje, E. T., Kapesa, A., Kamugisha, E., Mwita, S., & Swedberg, G. (2021). Artemether– lumefantrine and dihydroartemisinin– piperaquine treatment outcomes among children infected with uncomplicated Plasmodium falciparum malaria in Mwanza, Tanzania. Tropical Medicine and Health, 49(1), 94. https://doi.org/10.1186/s41182-021-00383-3
Mwesigwa, J., Parikh, S., McGee, B., German, P., Drysdale, T., Kalyango, J. N., Clark, T. D., Dorsey, G., Lindegardh, N., Annerberg, A., Rosenthal, P. J., Kamya, M. R., & Aweeka, F. (2010). Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrobial agents and chemotherapy, 54(1), 52–59. https://doi.org/10.1128/AAC.00679-09
Omondi, P., Burugu, M., Matoke-Muhia, D., Too, E., Nambati, E. A., Chege, W., Musyoka, K. B., Thiongo, K., Otinga, M., Muregi, F., & Kimani, F. (2019). Gametocyte clearance in children, from western Kenya, with uncomplicated Plasmodium falciparum malaria after artemether-lumefantrine or dihydroartemisinin-piperaquine treatment. Malaria journal, 18(1), 398. https://doi.org/10.1186/s12936-019-3032-3
Peatey, C., Chen, N., Gresty, K., Anderson, K., Pickering, P., Watts, R., Gatton, M. L., McCarthy, J., & Cheng, Q. (2021). Dormant Plasmodium falciparum parasites in human infections following Artesunate therapy. The Journal of Infectious Diseases, 223(9), 1631–1638. https://doi.org/10.1093/infdis/jiaa562
Rasmussen, C., Alonso, P., & Ringwald, P. (2022). Current and emerging strategies to combat antimalarial resistance. Expert review of anti-infective therapy, 20(3), 353–372. https://doi.org/10.1080/14787210.2021.1962291
Sevene, E., Banda, C. G., Mukaka, M., Maculuve, S., Macuacua, S., Vala, A., Piqueras, M., Kalilani- Phiri, L., Mallewa, J., Terlouw, D. J., Khoo, S. H., Lalloo, D. G., & Mwapasa, V. (2019). Efficacy and safety of dihydroartemisinin-piperaquine for treatment of Plasmodium falciparum uncomplicated malaria in adult patients on antiretroviral therapy in Malawi and Mozambique: An open label non-randomized interventional trial. Malaria Journal, 18(1), 277. https://doi.org/10.1186/s12936-019-2909-5
van der Pluijm, R. W., Amaratunga, C., Dhorda, M., & Dondorp, A. M. (2021). Triple Artemisinin-Based Combination Therapies for Malaria – A New Paradigm? Trends in parasitology, 37(1), 15–24. https://doi.org/10.1016/j.pt.2020.09.011
Warsame, M., Hassan, A. M., Hassan, A. H., Jibril, A. M., Khim, N., Arale, A. M., Gomey, A. H., Nur, Z. S., Osman, S. M., Mohamed, M. S., Abdulrahman, A., Yusuf, F. E., Amran, J. G. H., Witkowski, B., & Ringwald, P. (2019). High therapeutic efficacy of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Somalia. Malaria Journal, 18(1). https://doi.org/10.1186/s12936-019-2864-1
World Health Organization. (2014). From malaria control to malaria elimination: A manual for elimination scenario planning. WHO Regional Office for Africa. https://www.afro.who.int/publications/malaria-control-malaria-elimination-manual-elimination-scenario-planning
